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Abstract
Background: The World Health Organization (WHO) has recommended guidelines for a HIV drug resistance (HIVDR) survey
for resource-limited countries. Eligibility criteria for patients include age below 25 years in order to focus on the prevalence
of transmitted HIVDR (tHIVDR) in newly-infected individuals. Most of the participating sites across Africa have so far reported
tHIVDR prevalences of below 5%. In this study we investigated whether the rate of HIVDR in patients ,25 years is
representative for HIVDR in the rest of the therapy-naı¨ve population.
Methods and Findings: HIVDR was determined in 88 sequentially enrolled ART-naı¨ve patients from Mwanza, Tanzania
(mean age 35.4 years). Twenty patients were aged ,25 years and 68 patients were aged 25–63 years. The frequency of
HIVDR in the study population was 14.8% (95%; CI 0.072–0.223) and independent of NVP-resistance induced by prevention
of mother-to-child transmission programs. Patients .25 years had a significantly higher HIVDR frequency than younger
patients (19.1%; 95% CI 0.095–0.28) versus 0%, P = 0.0344). In 2 out of the 16 patients with HIVDR we found traces of
antiretrovirals (ARVs) in plasma.
Conclusions: ART-naı¨ve patients aged over 25 years exhibited significantly higher HIVDR than younger patients. Detection
of traces of ARVs in individuals with HIVDR suggests that besides transmission, undisclosed misuse of ARVs may constitute a
significant factor in the generation of the observed high HIVDR rate. The current WHO tHIVDR survey that is solely focused
on the transmission of HIVDR and that excludes patients over 25 years of age may therefore result in substantial
underestimation of the prevalence of HIVDR in the therapy-naı¨ve population. Similar studies should be performed also in
other areas to test whether the so far reported optimistic picture of low HIVDR prevalence in young individuals is really
representative for the rest of the ART-naı¨ve HIV-infected population.
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Introduction
The World Health Organization (WHO), together with the
Joint United Nation Programme on AIDS (UNAIDS) and other
partners pursue the goal of providing worldwide access to ART
[1]. In most African countries the ART roll-out [2] takes place in a
context of a medical infrastructure with limited resources and a
low number of available antiretroviral drugs and HIV infection is
treated with standardised first- and second-line ART regimens.
Since 2004, a nation-wide care and treatment program has
been implemented for HIV-infected individuals in Tanzania.
Patients receive their antiretroviral medication free of charge in
more than 200 nationwide Care and Treatment Centers (CTCs)
and by the end of 2007 more than 165.000 eligible patients have
been started on ART. Patients eligible for ART belong to one of
the following three groups: a) patients with WHO clinical stage
irrespective of their CD4 counts, b) patients with WHO clinical
stage 3 and CD4 counts below 350/ml and c) all patients with
CD4 counts ,200/ml, regardless of their clinical symptoms [3].
The first-line regimens consist of a combination of zidovudine/
lamivudine (AZT/3TC) or stavudine/lamivudine (d4T/3TC)
together with nevirapine (NVP) or efavirenz (EFV). After therapy
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failure, a second-line regimen that includes abacavir/didanosine
(ABC/ddI) in combination with liponavir or saquinavi boosted
with ritonavir (LPV/r or SQV/r) is used [3]. Neither viral load
monitoring nor resistance testing are routinely done. HIV-
positive pregnant women have been offered participation in a
prevention of mother-to-child transmission (PMTCT) pro-
gramme since 2004 consisting of one single dose of NVP for
the mother at onset of labour, followed by a single dose of NVP
for the newborn within 72 hours after delivery. Since 2009, a
combination therapy of AZT, NVP and 3TC is recommended for
PMTCT at sites that have the possibility to offer and monitor this
ARV regimen [3].
Although ARV therapy is now available free of charge for
eligible patients, ARVs are also sold on the black market in
Tanzania. We do not know to which extent this phenomenon
contributes to self-medication, especially because these drugs are
quite expensive when not being prescribed. However, the fear of
stigmatization when receiving ARV regimens at HIV CTCs as
well as a general lack of knowledge of HIV treatment guidelines
could be factors promoting unadvised medication.
The large-scale availability of first- and second-line ART
regimens in a resource-limited area bears the risk of an unnoticed
evolution of drug-resistant quasispecies in treated patients and
their subsequent transmission into the ART-naı¨ve population [4].
The WHO therefore recommends the monitoring of HIVDR
among newly infected individuals in order to estimate the extent
to which transmission of drug resistant HIV occurs, classifying
HIVDR prevalence into three groups (low: ,5%, moderate 5–
15%, and high .15%) [5]. Mandatory criteria for inclusion into
the WHO-initiated transmitted HIVDR (tHIVDR) surveillance
are a) age below 25 years, b) no previous pregnancies, and c) no
previous ART use [6]. Their rationale is to exclude people with
long-standing infections, infected before ART was widely
available in the country, or patients previously exposed to
antiretrovirals (ARVs), e.g. through participation in PMTCT
programs [5].
So far, the reported prevalence of tHIVDR in eligible patient
populations is below 5% across Africa [7,8,9,10,11,12] and only
for some areas moderate HIVDR rates have been reported in
some studies [11]. These rather optimistic findings are in sharp
contrast to observations from sub-Saharan Africa, that a
significant proportion of HIV patients who start first-line ART
encounter early virological failure within the first 12 months of
therapy [13,14,15]. This may suggest that the true prevalence of
HIVDR in patients presenting for ART initiation might be
significantly higher than estimated from tHIVDR data.
Therefore, we hypothesized that HIVDR prevalence may differ
between people eligible for WHO tHIVDR surveillance and the
rest of the HIV-infected population. A systematic underestimation
of the prevalence of HIVDR would misguide health care decision
makers in resource-limited countries and result in fatal conse-
quences for ART efficacy. In this study we determined the
frequency of HIVDR in ART-naı¨ve patients in Tanzania aged
below and above the WHO-initiated tHIVDR survey limit of 25
years of age.
Methods
Ethics statement
The study was approved by the National Institute for Medical
Research (Tanzania), Bugando Centre Ethical Board, and
Ministry of Health (Tanzania). All patients gave written informed
consent. All clinical investigations have been conducted according
to the principles expressed in the Declaration of Helsinki.
Patients
In this study we investigated samples from HIV patients
enrolled in the clinical trial ProCort1 (trial name: ‘‘ProCort1’’;
registry: ClinicalTrials.gov; registration number: NCT01299948).
ProCort1 is a randomized, double-blinded placebo-controlled trial
testing low-dose (5 mg/day) prednisolone on HIV disease
progression in ART-naive patients who are not yet eligible for
ART. According to ProCort1 inclusion criteria, patients were HIV
positive but ART-naive with CD4+ cell counts .300 cells/ml and
no other clinical conditions that require ART. For the ProCort1
trial, a total number of 416 consecutively enrolled HIV patients
were initially screened. 90 patients presented as screening failures,
mostly (about 80%) because of CD4 counts below 300 cells/ml.
The other screening failures were due to TB-coninfections,
abnormal blood parameters (HB, ALT, AST, creatinin) or
diabetes. Plasma and peripheral blood mononuclear cells (PBMC)
were collected from every patient at baseline and at 12 later time
points covering a time span of two years. The study was performed
at the Bugando Medical Centre in Mwanza (Tanzania).
Samples and bulk sequencing reaction
75 samples of DNA isolated from frozen PBMC and 55 samples
of RNA isolated from frozen plasma collected from 120 randomly-
selected patients (from 10 patients both DNA and RNA were
isolated) enrolled in the ProCort study were amplified as described
[16] by HIV-Pol-specifc PCR or RT-PCR, respectively. A positive
PCR reaction was yielded from 46 plasma samples and 48 PBMC
samples, corresponding to a recovery rate of 84% (46/55) from
plasma and 64% (48/75) from PBMC samples. PBMCs used for
these experiments had a low viability, probably a result of
suboptimal freezing conditions during transport or storage, which
may explain the low PCR recovery rate from these samples. Bulk-
sequencing of the PCR products was performed as described [16].
Sequences were submitted to GenBank, accession numbers
HM572334–HM572422.
HIV drug resistance and subtype analysis
For analysis of resistance-associated mutations (RAM), the
FASTA files were submitted to Stanfords HIV drug resistance
database [17]. The 2009 HIVDR surveillance database [18] was
used to identify mutations eligible for the WHO HIVDR
surveillance analysis. HIV subtype analysis was performed by
phylogenetic analysis of the FASTA files as described [16].
Therapeutic Drug Monitoring (TDM)
Plasma samples collected at baseline from patients with RAM
were subjected to TDM for the detection of Efavirenz, Nevirapine,
Nelfinavir, Saquinavir, Atazanavir, and Lopinavir as described
[19,20]. TDM is a well-established investigation in HIV-patients
during antiretroviral treatment and part of international guide-
lines. The methods to determine plasma concentrations of HIV-
protease inhibitors (PI) and non-nucleoside reverse transcriptase
inhibitors (NNRTI) are highly specific and sensitive. In the
HPLC/GC methods used in the study, the limit of detection
(LOD) of nevirapine was determined at 2 ng/ml, the lower limit of
quantification (LLQ) of nevirapine was reached at a concentration
of 10 ng/ml. For efavirenz the LOD was 3 ng/ml, and the LLQ
was 25 ng/ml.
Statistical Analysis
Patients in different age groups were sorted according to the
absence or presence of HIVDR in a 262 contingency table.
Frequency of HIVDR in different age groups was compared using
High HIVDR in Tanzania
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Fisher’s exact probability test. P,0.05 was considered as
statistically different. 95% confidence intervals (CI) were calculat-
ed using GraphPad Prism Software. 95% CIs were truncated at
0.000 if lower CI was negative.
Results
Patient characteristics
The sequences analyzed in this study derive from 88 ART-naı¨ve
HIV-infected patients in Mwanza, Tanzania, enrolled in the
clinical trial ProCort1 (mean age 35.4 years, 78% female) (Table 1).
The mean duration since HIV diagnosis was 1.3 years. Twenty
patients were younger than 25 years and thus fulfilled the age
criteria of the WHO tHIVDR surveillance program, while 68
patients (77%) were aged above 25. This corresponds to the typical
age distribution of ART-naı¨ve patients in Mwanza.
High frequency of drug-resistant HIV
With bulk sequencing reactions from PBMC-derived DNA (46
cases) and plasma-derived RNA (42 cases) we detected HIV-pol
mutations associated with drug resistance in 16 of 88 patients
(18.2%; 95% CI 0.100–0.264) (Table 2). Only four of the 16 RAM
were initially detected from plasma and 12 from PBMC. In order
to investigate if there is any difference in RAM frequency in the
two compartments, we sequenced plasma specimens from five
patients who were initially tested positive for RAM with PBMC-
derived DNA and found the same RAM also in plasma. In five
additional cases we retested RAM-negative patients who were
initially tested in plasma and found no sequence differences in
PBMC (data not shown). Three of the 16 samples had RAM
associated with polymorphic positions (T98G; T69N; one patient
with both E44D and V118I) that are excluded from WHO
tHIVDR surveillance [18]. We hence use the term ‘‘WHO-
defined HIVDR’’ to refer to mutations listed by WHO for
tHIVDR surveillance [18] and the term ‘‘HIVDR’’ on its own to
refer to all RAM according to the Stanford Database, irrespective
of their association with polymorphic sites [17]. The frequency of
‘‘WHO-defined HIVDR’’ was 14.8% (13/88, 95% CI 0.072–
0.223) in the entire study population (Fig. 1A, white bar).
Age-dependent frequency of drug-resistant HIV
The occurrence of RAM was highly correlated with the age
(Fig. 1). WHO-defined HIVDR frequency was 0% (0/20) in
patients aged under 25 but 19.1% (13/68; 95% CI 0.095–0.28) in
patients older than 25 years (Fig. 1A), which is statistically
significantly different (p = 0.0344, Fishers exact test).
As depicted in figure 1B, frequency of HIVDR seems to peak
in middle-aged patients, although the number of patients in each
age-group is too small in order to reach statistical significance.
Some of the patients presented with two or three different RAM
(Fig. 1C). This ‘‘RAM burden’’, i.e. the number of different RAM
contributing to resistance against ARVs per individual, correlates
with impairment of a greater spectrum of classes of ARVs
(Fig. 1D).
Clinical impact of the RAM
The resistance pattern detected could severely limit the options
for ART once the patients become eligible for antiviral therapy.
About every fifth patient (21.6%; 8/37) in the group 25–39 years
has a predicted reduced susceptibility towards the local first-line
ART regimens according to Stanford Database (Fig. 2A). Without
prior resistance testing, prescribing this regimen would result in
insufficient suppression of viral replication, likely leading to a rapid
development of further mutations conferring resistance to other
components of the regimen and – finally – to complete virological
failure. Even more concerning are the findings that the efficacy of
the local second-line regimens is also affected by the detected
mutation profile: a) 24% (9/37) of the patients aged between 25–
39 have RAM that correspond to low- and high-level resistance
towards ARVs included in the local second-line regimens
according to Stanford Database (Fig. 2B) and b) 8 out of 9
patients (89%) in this age group with predicted reduction of first-
line efficacy also have a predicted reduction of second-line efficacy
(Fig. 2C). Related to the whole study population, these numbers
Table 1. Demographic patient characteristics of the study population.
PCR-negative PCR-positive PCR-positive PCR-positive
all Age,25 years Age$25 years
total n =120 n=32 n=88 n=20 n=68
Age (years) 35.0612.2 35.2611.3 22.661.5 38.9610.1
(21.1–59.0) (18.6–63.7) (18.7–24.9) (25.2–63.7)
Gender 77% female 78% female 95% female 75% female
CD4+ T-Cell count (cells/ml) 6646299 4906222 5346215 4786223
(224–1435) (99–1056) (140–1037) (99–1056)
time since first diagnosis (years) 1.3062.75 1.3061.75 0.7760.83 1.4561.92
(0.05–15.09) (0.04–9.97) (0.05–2.99) (0.04–9.97)
Sequencing from PBMC (%) compared to plasma -- 52% 50% 53%
Clinical stage (CDC) A1 56% 33% 45% 29%
Clinical stage (CDC) A2 38% 51% 45% 53%
Clinical stage (CDC) B1 0% 9% 10% 9%
Clinical stage (CDC) B2 6% 7% 0% 9%
The study population consisted of 120 ART-naive HIV-1 infected adults. PBMC- or plasma samples from 88 patients yielded amplicons for the bulk sequencing reaction.
Data are expressed as means 6 S.D. and range in parentheses. Patients with CD4 counts ,200/ml at sample date initiated ART if CD4 counts remained below 350/ml
four weeks later.
doi:10.1371/journal.pone.0023091.t001
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could translate into complete ART failure (first- and second-line)
in about 9% (8/88) of all patients.
Long-term persistence of RAM
In order to determine the long-term persistence of RAM in the
16 patients with baseline RAM, plasma specimens collected up to
21 month later were analyzed. Three different scenarios were
observed: In five patients the initially-detected RAM persisted, in
six patients RAM detected at baseline became undetectable later,
and in five patients RAM that were undetected at baseline were
found in follow-up samples (Table 3).
Therapeutic drug monitoring
Baseline plasma samples of 14 patients with RAM were
screened for the presence of antiretroviral substances. We detected
traces of efavirenz (160 ng/ml, sample number TZ.08.014495)
and nevirapine (202 ng/ml, sample number TZ.08.017176) in two
samples (Table 2). These drugs are, however, unrelated to the
RAM detected in these patients (M184I and M41L). For one
patient (TZ.08.017195) in which we detected K103 that confers
resistance to EFV or NVP and was stable for at least 18 months,
we screened additional plasma samples donated at 3, 6, 12 and 18
months after initial sampling and found no traces of either drug.
HIV-1 subtype distribution
Subtype analysis identified seven different clusters that can be
divided into different HIV subtype groups, including A1 (34% of
the samples), B (1%), C (26%), D (28%), CRF10_CD (4%) and
recombinants A1D (7%) (Fig. 3). These findings are in line with
previous reports from the area [10,21].
Discussion
The frequency of RAM in our ART-naı¨ve study group is much
higher than expected from hitherto reported prevalence rates of
below 5% from WHO tHIVDR threshold surveys across Africa
[22]. This this difference is probably mainly attributed to the
different criteria for choosing patients for HIVDR surveillance:
The WHO surveillance criteria define eligible patients as
presumably recently infected patients below 25 years of age with
CD4+ T-cell counts above 500 cells/ml, and – if female - restricted
to women without prior history of pregnancies to avoid PMTCT-
induced resistance. Our study population, in contrast, consists of
HIV patients with a probably slightly longer history of infection
(1.3061.75 years since diagnosis) with a mean age of 35.4 years, a
mean baseline CD4+ T-cell count of 483 cells/ml and amongst
females predominantly multigravidae (Table 1).
By applying the age criteria of WHOHIVDR surveillance to our
analysis, we would have concluded that the prevalence of drug
resistant HIV in the Mwanza region is below 5% similar to what
was reported for the Dar es Salaam region in Tanzania in 2008 [23]
and from most other HIVDR surveillance sites across Africa so far
[7,8,9,10,11,12]. However, the true frequency of HIVDR in our
study population is much higher: 14.7%, if mutations at
polymorphic sites are excluded and even 18.2% if they are included.
Table 2. HIVDR in the Mwanza cohort.
Age
(years)
Sample
number NRT RAM
NNRTI
RAM PI RAM
Affected drug
(low-level
resistance)
Affected drug
(high-level
resistance) TDM
time since
HIV test
(years)
20.5 TZ.09.032647 A98G1 NVP neg. 0.31
25.4 TZ.08.029746 D30N ATV NFV neg. 0.58
26.4 TZ.08.017184 M41L D4T, AZT, ddI, ABC neg. 1.05
28.0 TZ.08.014495 M184I ABC 3TC, FTC EFV 0.33
30.2 TZ.08.022112 M184I G190E ABC 3TC, FTC, NVP, EFV neg. 8.3
32.2 TZ.09.001336 G73S SQV, NFV, ATV neg. 0.28
32.4 TZ.09.001332 M184I K103N ABC 3TC, NVP, EFV, DLV neg. 0.18
33.2 TZ.08.017176 M41L D4T, AZT, ddI, ABC NVP 2.50
33.7 TZ.08.023280 V75A D4T, ddI neg. 1.63
36.7 TZ.08.017197 T215I K103N V82T D4T, AZT, ddI, ABC,
SQV/r, LPV/r, ATV, NFV
NVP, EFV, DLV n.d. 2.81
38.7 TZ.09.001323 G190E G73S SQV/r, NFV,ATV, DLV NVP, EFV neg. 1.06
42.6 TZ.09.006017 V82A LPV/r, SQV/r, ATV, NFV neg. 4.60
44.9 TZ.10.002035 T69N2 ddI negative 1.14
46.7 TZ.08.017195 K103N NVP, EFV, DLV n.d. 0.38
46.8 TZ.10.003309 E44D3
V118I3
3TC neg. 0.15
51.4 TZ.08.017193 Y188H NVP, EFV, DLV neg. 0.04
RAM according to the Stanford HIV Drug Resistance Database [17] in 16/88 baseline samples. Mutations associated with a score of 60 were attributed as high-level
resistance-associated mutations (RAM) and mutations with a score of 10–35 were attributed as low-level RAM. Mutations listed for WHO HIVDR surveillance [18] are
indicated in bold. Superscripted numbers identify the reasons for excluding the respected mutations from the HIVDR list: 1) nonpolymorphic, but at highly polymorphic
position; 2) polymorphic position in subtypes B, F, CRF01_AE; 3) polymorphic in multiple subtypes. ABC: Abacavir; ATV: Atazanavir; AZT: Zidovudine; ddI: Didanosine;
DLV: Delaviridine; D4T: Stavudine; EFV: Efavirenz; FTC: Emtricitabine; LPV: Lopinavir; NFV: Nelfinavir; NVP: Nevirapine; SQV: Saquinavir; 3TC:Lamivudine [29]. Underlined
drugs are part of the local first line regimens, double line underlined drugs are part of local second line regimens. Data derived from 88 sequenced samples. Therapeutic
drug monitoring (TDM) was performed from plasma samples collected at baseline for NNRTIs (Efavirenz and Nevirapine) and PIs (Nelfinavir, Saquinavir, Atazanavir and
Lopinavir).
doi:10.1371/journal.pone.0023091.t002
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This alarmingly high frequency of HIVDR could have been
generated by two different ways: a) by direct transmission of drug
resistant viruses from sexual partners carrying the resistant virus or
b) by selection from the natural pool of quasispecies in each
individual patient following undisclosed antiretroviral drug
experience. It is reasonable to suggest that both factors may have
contributed to the observed high frequency of RAM in our
Tanzanian study group.
Intra-patient generated drug resistance in ART-naive patients
can either result from episodes of NVP monotherapy of pregnant
women during PMTCT or from undisclosed (self-) medication
with ARVs. To exclude PMTCT-generated NVP resistances from
tHIVDR surveillance, the WHO criteria exclude multigravidae,
which results in excluding many, if not the majority of women.
In our study group we identified seven patients with NVP
resistance (Table 4). We can exclude PMTCT as a possible cause
for the occurrence of the NVP resistance mutation in five of them
(71%), because the patients are either male (two cases) or the
pregnancies date before HIV infection was diagnosed (three cases).
In one additional case we were unable to ascertain the patient’s
PMTCT status and in only one case we positively identified a
patient who actually received PMTCT. Therefore, the vast
majority of NVP resistance in our study group is obviously
unrelated to PMTCT. The two NVP resistance mutations that can
be potentially attributed to PMTCT have, however, no influence
on the overall HIVDR frequency in our study group, as the
respective patients (TZ.09.001332, TZ.09.001323) present with
multiple RAM against other ARVs that are completely unrelated
to the Tanzanian PMTCT program. Since these other mutations
(M184I and G73S, respectively) must have been acquired
independently of PMTCT, there is no reason to exclude these
two patients from the analysis.
As for undisclosed self-medication, all patients who presented
with RAM repeatedly reported that they were treatment-naı¨ve
(except for those who participated in PMTCT programs) and also
their medical records – if available - were negative in this respect,
Figure 1. The frequency of HIVDR is age-dependent. HIVDR was determined by bulk sequencing from ART-naı¨ve patients. A.: Frequency of
WHO-defined HIVDR in patients aged under 25 years (n = 20, left bar), patients aged over 25 years (n = 68, middle bar), and in the total study
population (n = 88, right white bar). B: Frequency of WHO-defined HIVDR peaks in different age groups. Numbers in brackets indicate the number of
individuals tested in each age group. Data as means 6 S.E.M.. For statistical analysis, Fisher’s exact test was performed. Differences with a P,0.05
were regarded as statistically significant. C: Number of WHO-defined RAM per individual (‘‘RAM burden’’). D: Number of affected antiretroviral drug
classes (NRTI, NNRTI, PI) per individual in relation to the number of WHO-defined RAM per individual.
doi:10.1371/journal.pone.0023091.g001
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Figure 2. HIVDR affects efficacy of local first- and second-line ART regimens. Effects of HIVDR (high- and low-level resistances) on drugs
included in the local antiretroviral regimens. A: Effects on local first-line ART regimen. HIVDR that affects at least one of the drugs included in first-line
therapy (AZT/D4T plus 3TC plus NVP/EFV) scored positive. B: Effects on local second-line ART regimen. HIVDR that affects at least one of the drugs
included in second-line therapy (ddI/ABC plus LPV/SQV plus RTV) scored positive. C: Proportion of patients with HIVDR that affects first-line ART
regimen who also carry HIVDR that affects second-line ART regimen.
doi:10.1371/journal.pone.0023091.g002
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suggesting that not only the majority of NVP mutations but also a
great proportion of the other detected mutations were acquired by
transmission.
In an attempt to challenge the given disclosure about the
patients’ drug status, we used TDM as a forensic method in order
to determine whether the patient has taken NNRTIs or PIs
within the past 1–2 weeks, the time window in which we can
detect these drugs in plasma samples [24,25]. Of the 16 patients
who presented with RAM, traces of ARVs were detected in two
(Table 2), indicating that at least some of the patients gave a false
statement regarding their drug status. We can almost exclude that
the patients studied here received ARVs by CTCs, as their health
status was still good enough to be eligible for ART and any
clinically-advised antiretroviral medication would have been
documented in their medical records – which were negative in
this regard. To our knowledge, this is the first reported evidence
for undisclosed self-medication with ARVs in Africa, a phenom-
enon that has unfortunately not yet been addressed by systematic
analyses. The detected ARVs were, however, not related to the
RAM found in these patients, so that the undisclosed medication
with ARVs might just have been an epiphenomenon and the
detected RAM may nonetheless have been acquired by
transmission.
According to WHO criteria, these two patients are not eligible
for tHIVDR survey, because they were (as found by experimental
evidence) not ARV naı¨ve. Even if we excluded these patients from
our analysis, HIVDR frequency would still be 12.5% (11/88) and
therefore much higher than anticipated from previous reports
from Tanzania [23]. However, we did not exclude the patients
from our analysis for the following reasons: a) First and foremost,
the aim of our study is not to fulfil current WHO criteria as good
as possible and to see how close we can get to previous-published
results, but rather to challenge these very criteria by looking into a
therapy-naı¨ve population as it is, i.e. not being filtered by
additional criteria concerning age or drug naivety (not to be
mistaken with therapy naivety!). In our case, the frequency of
HIVDR in patients who have never before received medically-
advised antiretroviral therapy is in the range of 15% and this
constitutes a severe medical problem for future antiretroviral
therapy with predefined regimens - no matter how many patients
we exclude from our analysis for not fulfilling WHO criteria for
whatever reasons. b) The availability of ARVs on the black market
is a known phenomenon in many sub-Saharan countries and there
is no reason to believe that undisclosed self-medication is a
phenomenon restricted to our study population. It is rather
plausible to assume that self-medication with ARVs (be it from
black-market supplies or by drug-sharing within a family) is
inevitably connected to ART roll-out programs and surveys to
monitor the prevalence of HIVDR in therapy-naı¨ve patients
should not exclude this source of drug resistance. c) WHO criteria
do not include forensic methods to control whether the studied
populations are really drug-naı¨ve, and to our knowledge, drug
monitoring has not been done in any of the tHIVDR surveys
published so far.
In five out of the 16 RAM carriers we observed the emergence
of new RAM at later time points (Table 3). It seems very unlikely
Table 3. Long-term persistence of RAM.
Sample number RAM at baseline
Time to Follow-up
1 (months)
RAM at
Follow-up 1
Time to Follow-up
2 (months)
RAM at
Follow-up 2
TZ.09.032647 A98G 5 A98G n.a. n.d.
TZ.08.017184 M41L 11 M41L 18 M41L
persistent RAM TZ.08.017176 M41L 12 M41L 21 M41L
TZ.08.017195 K103N 13 K103NS, Y188HY 18 K103N
TZ.10.003309 E44D, V118I 21 E44D, V118I n.a. n.d.
TZ.08.029746 D30N 12 none n.a. n.d.
TZ.09.006017 V82A 18 none n.a. n.d.
RAM disappeared TZ.08.022112 M184I, G190E 15 Q151QR 18 none
TZ.09.001336 G73S 18 V179T n.a. n.d.
TZ.08.023280 V75A 12 T69ST 14 T69ST
TZ.08.017193 Y188H 6 L10V n.a. n.d.
TZ.08.022112 M184I, G190E 15 Q151QR 18 none
TZ.09.001336 G73S 18 V179T n.a. n.d.
new RAM TZ.08.023280 V75A 12 T69ST 14 T69ST
TZ.08.017193 Y188H 6 L10V n.a. n.d.
TZ.08.017195 K103N 13 K103NS, Y188HY 18 K103N
TZ.08.014495 M184I 6 no PCR product n.a. n.d.
TZ.09.001323 G190E, G73S 18 no PCR product n.a. n.d.
unclear TZ.09.001332 M184I, K103N n.a. n.d. n.a. n.d.
TZ.08.017197 T215I, K103N, V82T n.a. n.d. n.a. n.d.
TZ.10.002035 T69N n.a. n.d. n.a. n.d.
Of the 16 patients who presented with RAM at baseline, we analyzed plasma specimens collected at later time points (‘‘follow-up 1’’, ‘‘follow-up 2’’) for the presence of
RAM. We detected three different scenarios, including persistent RAM, disappearing RAM, and newly emerging RAM (some samples appear in more than one scenario).
Time to follow-up sample is indicated in months. In some cases, no PCR product from plasma samples could be generated. The investigation for long-term stability of
RAM is insofar incomplete as plasma specimens collected at later time points were not available (‘‘n.a.’’) for all patients, referred to as ‘‘n.d.’’ (not determined).
doi:10.1371/journal.pone.0023091.t003
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that these newly-detected RAM originate from superinfections
with drug-resistant viruses but rather that the emergence of these
RAM was either caused by recent misuse of ARVs or - probably
the more plausible interpretation – simply reflects a false-negative
result of the bulk sequencing method at baseline determination (for
discussion of bulk sequencing sensitivity see also below). In three
cases the RAM detected at baseline remained stable for more than
18 months. Two of these patients carried the mutation M41L and
one carried the mutation K103N. For both mutations a long-term
stability has been reported even in the absence of antiviral
medication [26].
In four of the 16 patients presenting with RAM, plasma samples
could be obtained from their HIV-infected partners. Two of these
could be sequenced and had the same RAM as their partners
(K103N detected in TZ08.017195 and the partner’s sequence
TZ09.028733, and M41L detected in TZ08.017176 and the
partner’s sequence TZ09.028732). In a phylogenetic analysis these
sequences clustered in direct neighbourhood to the partner’s
sequences (marked with ‘‘couple I’’ and ‘‘couple II’’ in Fig. 3). As it
is rather unlikely that a potential misuse of an ARV generates
exactly the same RAM profile in both partners (many different
RAMs can become selected by a given ARV), it is reasonable to
assume that the respective RAM was received by transmission,
although we cannot say in which direction the transmission
occurred.
Irrespective of whether the observed high frequency of RAM is
predominantly caused by transmission or by selection with
undisclosed medication with ARVs, such a high frequency of
RAM in patients who are likely to start ART in the near future
translates into an expected reduction of first- and second-line ART
regimen efficacy. The full extent of the problem may be even
greater, as we generated our data from bulk sequencing reactions,
which are known to underestimate the number of RAM, because
they fail to reliably detect mutations if the respective quasispecies
contribute less than 20–30% to the total viral population [27].
More sensitive techniques, such as real time PCR-based resistance
testing, show that bulk sequencing considerably underestimates the
true frequency of HIVDR [28].
If the observed level of HIVDR in our study group is
representative of other regions of Africa, this would affect the
settings in which ART roll-out programmes are being implement-
ed. The current WHO surveillance criteria bear the danger of
answering a merely academic question (i.e. the transmission rate of
resistant viruses in people aged under 25), whereas the clinical
reality has to deal with pre-existing HIVDR in all patients eligible
for ART, irrespective of their origin (transmitted or intrapatient-
selected) and irrespective of the patient’s age. Beyond that, it is
questionable whether the under-25 year olds are a representative
‘‘sentinel group’’ for HIVDR transmission in the rest of the
population, because important social parameters that presumably
affect the rate of resistance transmission, such as promiscuity or the
ART status of the sexual partners are likely to significantly differ
between different age groups, which may compromise the current
resistance surveys. Moreover, the (so far excluded) patients over 25
years of age represent a significant proportion in the group of
patients eligible for ART. Over the years at Bugando Medical
Centre, the proportion of those older than 25 years amongst
patients eligible for ART has been between 70 to 80 percent. This
is similar to the age distribution in our study group, which in this
respect quite accurately pictures the characteristics of patients
seeking for ART at Bugando Medical Center. Our study
population was, however, not intentionally designed to represent
the whole HIV-infected population in Mwanza, so that an
extrapolation of our data to the whole population in Mwanza
must be taken with caution. Moreover, the patients investigated in
this study have been reenrolled for an interventional clinical trial
Table 4. NVP resistance and PMTCT.
Sample number Gender PMTCT with NVP Birth dates of children First HIV diagnosis NVP resistance caused by PMTCT
TZ.09.032647 female none 2007 24.08.08 no
TZ.08.022112 male n.a. n.a. 24.09.04 no
TZ.09.001332 female unknown unknown 23.08.07 unclear
TZ.08.017197 female none 1989, 1993, 1995 16.04.07 no
TZ.09.001323 female yes 1990, 1992, 1994, 1996, 2004, 2006 26.01.06 possible
TZ.08.017195 female none 1992, 1993, 1995, 1997, 1999 22.05.07 no
TZ.08.017193 male n.a. n.a. 15.09.05 no
Patients with NVP resistance mutations were analyzed regarding PMTCT (with NVP monotherapy) as a possible cause for the emergence of the mutation. PMTCT as a
cause for the mutation’s appearance is discussed as ‘‘possible’’ if the mother received PMTCT; it is discussed as ‘‘unclear’’ if the PMTCT status and the dates of birth of
the children are unknown; for plausibility reasons PMTCT was excluded (‘‘no’’) as a trigger of the NVP mutation if the patient is either male or if a female patient
presented with unknown PMTCT history combined with the HIV infection being diagnosed only since the date of birth of the youngest child.
doi:10.1371/journal.pone.0023091.t004
Figure 3. Phylogenetic analysis of RT and PR sequences from the Tanzanian cohort. A neighbour-joining phylogenetic tree [30] was
constructed from the 88 patient derived HIV-1 sequences from the Tanzania cohort and the two partner-derived sequences. Reference sequences
were obtained from the Los Alamos HIV sequence database. The analyzed 1302 bp region includes the complete Protease and Reverse Transcriptase
coding region. The tree was constructed using Mega software version 4, and the evolutionary distances were calculated using the Kimura 2-
parameter method. The bootstrap consensus tree was inferred from 50000 replicates and values greater than 70% are indicated on the branch
lengths. The scale at the bottom left indicates the calculated genetic distances between the branches of the phylogenetic tree. Circles represent the
88 samples from our cohort. Black-dotted circles are without RAM, open-circled sequences are with RAM, open triangles are sequences with RAM
from HIV-infected partners of two study subjects, which were not included in the determination of HIVDR as these patients received ART. Sequences
without symbols are subtype reference sequences derived from Los Alamos database. The subtype is indicated at the end of each sequence name.
Relative subtype frequency: A1: 34%, A1D: 7%, C: 26%, CRF10_CD: 4%, D: 28%, B: 1%. Sequences isolated from two couples (couple I, couple II) with
NVP resistances.
doi:10.1371/journal.pone.0023091.g003
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(‘‘ProCort1’’), which may have caused a selection bias (like, for
instance, patients who agree to join an interventional trial may or
may not be more prone for self-medication with ARVs in the past
or to keep information about ARV misuse undisclosed). We
therefore refer to the term ‘‘frequency’’ rather than ‘‘prevalence’’
when describing the rate of RAM in our patient population.
WHO recommends the analysis of at least 34–47 specimens (34
if no mutations were found, $47 if one or more mutations are
detected within the first 34 sequences) of consecutively enrolled
patients for the threshold survey method in order to categorize
HIVDR as ,5%, 5–15% or .15% [18]. Here we analyzed 88
samples and the determined frequency of HIVDR is therefore
quite robust. Although we did find a frequency of HIVDR in the
range of 5–15% in our study group – a finding that in the context
of an expected low HIVDR rate is remarkable in itself – the most
important aspect of our study is that this relatively high frequency
of HIVDR would have remained completely unnoticed, if we
strictly applied the current age criteria (,25) of the WHO
threshold survey method to our analysis. The difference in
HIVDR between the two age groups was so pronounced that it
reached statistical significance despite the relatively low number of
only 20 studied patients aged below 25 years. On the other hand,
the estimation of a 0% HIVDR frequency in patients ,25 years
remains relatively uncertain, as the number of analyzed sequences
in this subgroup is smaller than recommended.
The most substantial argument in favor of an age restriction of
HIVDR surveys to patients younger than 25 years is probably the
intention to exclude as much as possible older infections that
reflect HIVDR transmission rates of the past rather than the
current situation. In our study, the mean time since HIV diagnosis
of the patients under 25 years old was 0.77 (60.19 SD) years with
a range of 0.05–2.99 years, compared to 1.45 (60.23 SD) years for
patients aged above 25 years (p = 0.1285, non-significant) (Table 1).
Moreover, 10 of 13 (77%) patients with HIVDR had a known
infection time within the range of the young age group, and 6 of 13
(46%) had infection times even below the average of the young
group (Table 2). This is in fact not very astonishing, as young
people in Tanzania are considered to be at substantial risk of HIV
infection by sexual intercourse already at the age of 15 [3] which is
still ten years away from the 25 years limit. Combined with an
asymptomatic phase of infection that can last on the one hand for
several years but on the other hand turns into a symptomatic
disease within less than a decade, it is not very surprising that the
asymptomatic (hence therapy-naı¨ve) individuals under and over 25
years of age do not significantly differ in time of infection. In the
light of this argument it appears that the age-restriction to under-
25 years old is not very effective in terms of selecting recent
infections. (The same argument would also apply for the intention
to minimize chances of being exposed to ARVs.) Moreover, given
that the over-25 years old – at least in our study - significantly
differ in HIVDR frequency compared to young patients, this age-
restriction may turn out to be even counterproductive in an
attempt to determine representative HIVDR prevalence rates.
Considering the high frequency of HIVDR in our study
population, we recommend the implementation of ART baseline
resistance testing in the Mwanza area, as HIVDR prevalence in
this area may have reached a critical level. In this regard, we
encourage the development of cheap, robust and easy-to-use
methods for detection of the commonest resistance-associated
mutations as well as the regular monitoring of viral load during
ART also in resource-limited settings. This would allow the
selection of suitable ARVs from the available repertoire and
prevent early therapy failure.
In conclusion, the results of this study demonstrate that the
frequency of HIVDR in our study population is much higher than
anticipated from the so-far published data of low tHIVDR levels in
Tanzania and sub-Saharan Africa in general, and – even more
important – that a restriction to patients ,25 years of age as
implemented in the current criteria of the WHO-initiated HIVDR
threshold survey would have dramatically failed to detect this. The
reason for this discrepancy is that the frequency of HIVDR
correlated with age, for it was totally absent in young individuals,
but surprisingly high in individuals being older than 25 years.
Sporadic and undisclosed misuse of ARVs may have contributed
to the observed high resistance rate. This indicates that the
exclusive focus on transmission of HIVDR in under 25-years old
as recommended by the current WHO HIVDR threshold survey,
instead of a broader approach that is open to HIVDR
accumulation by different mechanisms and across all age groups,
may fail to adequately monitor the effects of ART role out
programs on the spread of HIV drug resistance into the therapy-
naive population. We therefore recommend to perform similar
studies in other resource-limited areas to test whether the so far
reported optimistic picture of low HIVDR prevalence in young
individuals is really representative for the rest of the ART-naı¨ve
HIV-infected population.
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